Boundless Bio (BOLD) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Apr, 2026Executive summary
The annual meeting will be held virtually on June 15, 2026, with a record date of April 20, 2026, for voting eligibility.
Stockholders will vote on the election of two Class II directors and the ratification of KPMG LLP as the independent auditor for 2026.
The board recommends voting in favor of all proposals.
Proxy materials are primarily distributed electronically to reduce costs and environmental impact.
Voting matters and shareholder proposals
Proposal 1: Elect James Christensen, Ph.D., and Jennifer Lew as Class II directors until 2029.
Proposal 2: Ratify KPMG LLP as independent auditor for the fiscal year ending December 31, 2026.
Stockholders may submit proposals for the 2027 meeting by December 30, 2026, for inclusion in proxy materials.
Advance notice procedures for director nominations and other proposals are detailed in the bylaws.
Board of directors and corporate governance
The board will decrease from seven to five members after the meeting, with staggered three-year terms for each class.
All directors except the CEO are considered independent under Nasdaq rules.
The board is chaired by an independent director, with separate CEO and chair roles.
Committees include Audit, Compensation, and Nominating and Corporate Governance, all with independent members.
The board encourages diversity, independence, and relevant expertise in director selection.
Latest events from Boundless Bio
- ecDNA-targeted therapies offer a novel approach for hard-to-treat oncogene amplified cancers.BOLD
Corporate presentation8 May 2026 - Q1 2026 net loss narrowed to $13.6M; cash runway and KOMODO-1 trial support BBI-940 progress.BOLD
Q1 20268 May 2026 - Vote on two director nominees and auditor ratification at the June 2026 annual meeting.BOLD
Proxy filing28 Apr 2026 - Phase I trial launched for a novel oral degrader targeting ecDNA-driven breast cancers.BOLD
Leerink Global Healthcare Conference 202611 Mar 2026 - First-in-class Kinesin degrader BBI-940 targets ecDNA-driven cancers with early clinical progress.BOLD
Corporate presentation9 Mar 2026 - KOMODO-1 trial advances as focus shifts to BBI-940, with cash runway into late 2028.BOLD
Q4 20259 Mar 2026 - Phase 1 trial of BBI-940, an ecDNA-targeting degrader, is now enrolling breast cancer patients.BOLD
Guggenheim Securities Emerging Outlook: Biotech Summit 202612 Feb 2026 - Advancing ecDNA-targeted cancer therapies with strong leadership, robust pipeline, and solid funding.BOLD
Goldman Sachs 45th Annual Global Healthcare Conference3 Feb 2026 - Precision oncology programs target ecDNA-driven resistance, with pivotal data expected in 2025.BOLD
2024 Cantor Fitzgerald Global Healthcare Conference20 Jan 2026